List of Figures:
Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 17
Figure 4. North America Autoimmune Disease Diagnostics Market, 2021-2031, $ mn 20
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of North America Autoimmune Disease Diagnostics Market 25
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 28
Figure 9. Primary Restraints and Impact Factors of North America Autoimmune Disease Diagnostics Market 30
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of North America Autoimmune Disease Diagnostics Market 37
Figure 12. Breakdown of North America Autoimmune Disease Diagnostics Market by Product, 2021-2031, % of Revenue 43
Figure 13. North America Addressable Market Cap in 2022-2031 by Product, Value ($ mn) and Share (%) 43
Figure 14. North America Autoimmune Disease Diagnostics Market by Product: Assay Kits & Consumables, 2021-2031, $ mn 44
Figure 15. North America Autoimmune Disease Diagnostics Market by Product: Analyzers & Instruments, 2021-2031, $ mn 45
Figure 16. Breakdown of North America Autoimmune Disease Diagnostics Market by Test Type, 2021-2031, % of Sales Revenue 47
Figure 17. North America Addressable Market Cap in 2022-2031 by Test Type, Value ($ mn) and Share (%) 47
Figure 18. North America Autoimmune Disease Diagnostics Market by Test Type: Autoantibodies and Immunologic Tests, 2021-2031, $ mn 48
Figure 19. North America Autoimmune Disease Diagnostics Market by Autoantibodies and Immunologic Tests: Antinuclear Antibody Tests, 2021-2031, $ mn 50
Figure 20. North America Autoimmune Disease Diagnostics Market by Autoantibodies and Immunologic Tests: Anti-cyclic Citrullinated Peptide, 2021-2031, $ mn 51
Figure 21. North America Autoimmune Disease Diagnostics Market by Autoantibodies and Immunologic Tests: Enzyme-Linked Immunosorbent Assay (ELISA), 2021-2031, $ mn 52
Figure 22. North America Autoimmune Disease Diagnostics Market by Autoantibodies and Immunologic Tests: Rheumatoid Factor, 2021-2031, $ mn 53
Figure 23. North America Autoimmune Disease Diagnostics Market by Autoantibodies and Immunologic Tests: Thyroid Antibody Tests, 2021-2031, $ mn 54
Figure 24. North America Autoimmune Disease Diagnostics Market by Autoantibodies and Immunologic Tests: Other Autoantibodies and Immunologic Tests, 2021-2031, $ mn 55
Figure 25. North America Autoimmune Disease Diagnostics Market by Test Type: Inflammatory Marker Tests, 2021-2031, $ mn 56
Figure 26. North America Autoimmune Disease Diagnostics Market by Inflammatory Marker Tests: C-Reactive Protein (CRP), 2021-2031, $ mn 58
Figure 27. North America Autoimmune Disease Diagnostics Market by Inflammatory Marker Tests: Erythrocyte Sedimentation Rate (ESR), 2021-2031, $ mn 59
Figure 28. North America Autoimmune Disease Diagnostics Market by Inflammatory Marker Tests: Other Inflammatory Marker Tests, 2021-2031, $ mn 60
Figure 29. North America Autoimmune Disease Diagnostics Market by Test Type: Routine Laboratory Tests, 2021-2031, $ mn 61
Figure 30. North America Autoimmune Disease Diagnostics Market by Routine Laboratory Tests: Urinalysis, 2021-2031, $ mn 63
Figure 31. North America Autoimmune Disease Diagnostics Market by Routine Laboratory Tests: Complete Blood Count (CBC) Tests, 2021-2031, $ mn 64
Figure 32. North America Autoimmune Disease Diagnostics Market by Routine Laboratory Tests: Other Routine Laboratory Tests, 2021-2031, $ mn 65
Figure 33. North America Autoimmune Disease Diagnostics Market by Test Type: Other Test Types, 2021-2031, $ mn 66
Figure 34. Breakdown of North America Autoimmune Disease Diagnostics Market by Disease Type, 2021-2031, % of Sales Revenue 68
Figure 35. North America Addressable Market Cap in 2022-2031 by Disease Type, Value ($ mn) and Share (%) 68
Figure 36. North America Autoimmune Disease Diagnostics Market by Disease Type: Systemic Autoimmune Disease, 2021-2031, $ mn 69
Figure 37. North America Autoimmune Disease Diagnostics Market by Systemic Autoimmune Disease: Rheumatoid Arthritis, 2021-2031, $ mn 71
Figure 38. North America Autoimmune Disease Diagnostics Market by Systemic Autoimmune Disease: Systemic Lupus Erythematosus (SLE), 2021-2031, $ mn 72
Figure 39. North America Autoimmune Disease Diagnostics Market by Systemic Autoimmune Disease: Psoriasis/Psoriatic Arthritis, 2021-2031, $ mn 73
Figure 40. North America Autoimmune Disease Diagnostics Market by Systemic Autoimmune Disease: Other Systemic Autoimmune Diseases, 2021-2031, $ mn 74
Figure 41. North America Autoimmune Disease Diagnostics Market by Disease Type: Localized Autoimmune Disease, 2021-2031, $ mn 75
Figure 42. North America Autoimmune Disease Diagnostics Market by Localized Autoimmune Disease: Thyroiditis, 2021-2031, $ mn 77
Figure 43. North America Autoimmune Disease Diagnostics Market by Localized Autoimmune Disease: Multiple Sclerosis, 2021-2031, $ mn 78
Figure 44. North America Autoimmune Disease Diagnostics Market by Localized Autoimmune Disease: Inflammatory Bowel Disease, 2021-2031, $ mn 79
Figure 45. North America Autoimmune Disease Diagnostics Market by Localized Autoimmune Disease: Type 1 Diabetes, 2021-2031, $ mn 80
Figure 46. North America Autoimmune Disease Diagnostics Market by Localized Autoimmune Disease: Other Localized Autoimmune Diseases, 2021-2031, $ mn 81
Figure 47. Breakdown of North America Autoimmune Disease Diagnostics Market by Gender, 2021-2031, % of Revenue 83
Figure 48. North America Addressable Market Cap in 2022-2031 by Gender, Value ($ mn) and Share (%) 83
Figure 49. North America Autoimmune Disease Diagnostics Market by Gender: Female Patients, 2021-2031, $ mn 84
Figure 50. North America Autoimmune Disease Diagnostics Market by Gender: Male Patients, 2021-2031, $ mn 85
Figure 51. Breakdown of North America Autoimmune Disease Diagnostics Market by Age, 2021-2031, % of Revenue 87
Figure 52. North America Addressable Market Cap in 2022-2031 by Age, Value ($ mn) and Share (%) 87
Figure 53. North America Autoimmune Disease Diagnostics Market by Age: < 44, 2021-2031, $ mn 88
Figure 54. North America Autoimmune Disease Diagnostics Market by Age: 44 - 64, 2021-2031, $ mn 89
Figure 55. North America Autoimmune Disease Diagnostics Market by Age: > 64, 2021-2031, $ mn 90
Figure 56. Breakdown of North America Autoimmune Disease Diagnostics Market by End User, 2021-2031, % of Revenue 91
Figure 57. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 92
Figure 58. North America Autoimmune Disease Diagnostics Market by End User: Hospitals, 2021-2031, $ mn 93
Figure 59. North America Autoimmune Disease Diagnostics Market by End User: Clinics, 2021-2031, $ mn 94
Figure 60. North America Autoimmune Disease Diagnostics Market by End User: Diagnostic Labs, 2021-2031, $ mn 95
Figure 61. North America Autoimmune Disease Diagnostics Market by End User: Other End Users, 2021-2031, $ mn 96
Figure 62. Breakdown of North America Autoimmune Disease Diagnostics Market by Country, 2021 and 2031, % of Revenue 98
Figure 63. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 99
Figure 64. U.S. Autoimmune Disease Diagnostics Market, 2021-2031, $ mn 101
Figure 65. Canada Autoimmune Disease Diagnostics Market, 2021-2031, $ mn 103
Figure 66. Autoimmune Disease Diagnostics Market in Mexico, 2021-2031, $ mn 105
Figure 67. Growth Stage of North America Autoimmune Disease Diagnostics Industry over the Forecast Period 107
North America autoimmune disease diagnostics market is projected to grow by 7.3% annually in the forecast period and reach $4,009.5 million by 2031, driven by the growing prevalence of autoimmune diseases, the strong investment in research and development activities, the rise in technological advancements, increasing patient awareness and healthcare expenditure, and favorable government policies. Highlighted with 28 tables and 67 figures, this 125-page report “North America Autoimmune Disease Diagnostics Market 2021-2031 by Product (Assay Kits & Consumables, Analyzers & Instruments), Test Type (Autoantibodies and Immunologic, Inflammatory Marker, Routine Laboratory, Others), Disease Type (Systemic, Localized), Gender (Female, Male), Age (<44, 44-64, >64), End User (Hospitals, Clinics, Diagnostic Labs), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America autoimmune disease diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America autoimmune disease diagnostics market in every aspect of the classification from perspectives of Product, Test Type, Disease Type, Gender, Age, End User, and Country. Based on Product, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Assay Kits & Consumables • Analyzers & Instruments Based on Test Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Autoantibodies and Immunologic Tests • Antinuclear Antibody Tests • Anti-cyclic Citrullinated Peptide • Enzyme-Linked Immunosorbent Assay (ELISA) • Rheumatoid Factor • Thyroid Antibody Tests • Other Autoantibodies and Immunologic Tests • Inflammatory Marker Tests • C-Reactive Protein (CRP) • Erythrocyte Sedimentation Rate (ESR) • Other Inflammatory Marker Tests • Routine Laboratory Tests • Urinalysis • Complete Blood Count (CBC) Tests • Other Routine Laboratory Tests • Other Test Types Based on Disease Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Systemic Autoimmune Disease • Rheumatoid Arthritis • Systemic Lupus Erythematosus (SLE) • Psoriasis/Psoriatic Arthritis • Other Systemic Autoimmune Diseases • Localized Autoimmune Disease • Thyroiditis • Multiple Sclerosis • Inflammatory Bowel Disease • Type 1 Diabetes • Other Localized Autoimmune Diseases Based on Gender, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Female Patients • Male Patients Based on Age, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • < 44 • 44 - 64 • > 64 Based on End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals • Clinics • Diagnostic Labs • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of the regional market by country and split of key national markets by Product, Disease Type, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott Laboratories Beckman Coulter, Inc. Biomerieux SA Bio-rad Laboratories Inc. F. Hoffmann-la Roche Ltd. Hemagen Diagnostics Inc. Myriad Genetics Inc. PerkinElmer Inc. (Euroimmun AG) Quest Diagnostics Inc. Siemens Healthineers Inc. Thermo Fisher Scientific Inc. Trinity Biotech PLC Werfen Company (Inova Diagnostics Inc.) (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More